Medscape Teriflunomide is an immunomodulator with anti-inflammatory properties. Approval is based on results of a program of phase 3 trials. Results of the TEriflunomide Multiple Sclerosis (TEMSO) trial, published in the New England Journal of Medicine in 2011, ...
Gastroenterology & Endoscopy News Concomitant immunomodulator use also was predictive of response. “This is an important study that demonstrates that even if patients discontinue use of an anti-TNF due to reactions or loss of response, they can safely be restarted on the same drug,” Dr.
Healio TSO, which are porcine whipworm eggs, are an immunomodulator that regulates T cells and proinflammatory cytokines, according to the release. Its use as a UC treatment follows positive safety and efficacy results from clinical trials of TSO as a therapy ... and more »
Wall Street Journal Inflectra is indicated for treatment of severe, active Crohn's disease in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who ... and more »
pharmabiz.com TSO (Trichuris suis ova or CNDO-201), the microscopic eggs of the porcine whipworm, is a novel, orally administered, natural immunomodulator that regulates T-Cells and pro-inflammatory cytokines. The use of TSO as a therapeutic is based on the "hygiene ...
Market Playground IL-12 is considered to be a very strong immunomodulator , but by using a synthetic approach with DNA IL-12 combined with OMS, side effects of recombinant forms of cytokines such as IL-2, IFN (approved for melanoma) alone are eliminated – the OMS ... and more »
Catster Some vets recommend using immune system-boosting medications like interferon and Lymphocyte T-Cell Immunomodulator , but the jury is still out on how effective these treatments are. Do you have an FeLV-positive cat? What have you done to keep him or ... and more »
4-traders (press release) MGN1703 is based on ® ("double Stem Loop Immunomodulator "), an innovative DNA-based TLR9 agonist developed by MOLOGEN. ® activates the immune system against tumor-associated by targeting various receptors on certain immune cells, primarily ... and more »
